Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Jazz Pharmaceuticals plc - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
JAZZ
Nasdaq
2830
www.jazzpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Jazz Pharmaceuticals plc
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
- Feb 5th, 2025 5:10 pm
JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline
- Jan 15th, 2025 6:57 pm
Jazz Pharmaceuticals plc (JAZZ): Analysts Recommend This 52-Week High Stocks Now
- Jan 15th, 2025 6:54 pm
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec 17th, 2024 9:15 pm
Jazz Pharmaceuticals Announces CEO Succession Plan
- Dec 16th, 2024 9:05 pm
Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist?
- Dec 14th, 2024 1:37 pm
Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch
- Dec 13th, 2024 1:00 pm
5 High ROE Stocks to Buy as Volatility Weighs on Markets
- Dec 11th, 2024 2:22 pm
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
- Dec 6th, 2024 9:05 pm
Jazz (JAZZ) Up 3.4% Since Last Earnings Report: Can It Continue?
- Dec 6th, 2024 4:31 pm
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
- Dec 5th, 2024 12:45 pm
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
- Dec 4th, 2024 9:15 pm
Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
- Dec 3rd, 2024 12:49 pm
Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet
- Nov 29th, 2024 2:55 pm
Why Jazz Pharmaceuticals (JAZZ) Is One of the Most Undervalued Pot Stocks to Buy?
- Nov 28th, 2024 10:50 am
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
- Nov 22nd, 2024 2:15 pm
Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler
- Nov 22nd, 2024 11:36 am
Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer
- Nov 21st, 2024 12:12 pm
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
- Nov 21st, 2024 12:19 am
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
- Nov 19th, 2024 9:05 pm
Scroll